399 related articles for article (PubMed ID: 20964457)
1. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
Subissi A; Monti D; Togni G; Mailland F
Drugs; 2010 Nov; 70(16):2133-52. PubMed ID: 20964457
[TBL] [Abstract][Full Text] [Related]
2. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
Bohn M; Kraemer KT
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
[TBL] [Abstract][Full Text] [Related]
3. Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use.
Jue SG; Dawson GW; Brogden RN
Drugs; 1985 Apr; 29(4):330-41. PubMed ID: 3158508
[TBL] [Abstract][Full Text] [Related]
4. The dermatopharmacologic profile of ciclopirox 8% nail lacquer.
Bohn M; Kraemer K
J Am Podiatr Med Assoc; 2000; 90(10):491-4. PubMed ID: 11107709
[TBL] [Abstract][Full Text] [Related]
5. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
Gupta AK; Fleckman P; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
[TBL] [Abstract][Full Text] [Related]
6. Ciclopirox nail lacquer: a brush with onychomycosis.
Gupta AK
Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
[TBL] [Abstract][Full Text] [Related]
7. Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis.
Aly R; Maibach HI; Bagatell FK; Dittmar W; Hänel H; Falanga V; Leyden JJ; Roth HL; Stoughton RB; Willis I
Clin Ther; 1989; 11(3):290-303. PubMed ID: 2663159
[TBL] [Abstract][Full Text] [Related]
8. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology.
Croxtall JD; Plosker GL
Drugs; 2009; 69(3):339-59. PubMed ID: 19275277
[TBL] [Abstract][Full Text] [Related]
9. Ciclopirox nail lacquer solution 8% in the 21st century.
Gupta AK; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S96-102. PubMed ID: 11051138
[TBL] [Abstract][Full Text] [Related]
10. Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective.
Gupta AK; Schouten JR; Lynch LE
Skin Therapy Lett; 2005 Sep; 10(7):1-3. PubMed ID: 16292454
[TBL] [Abstract][Full Text] [Related]
11. The hydroxypyridones: a class of antimycotics of its own.
Korting HC; Grundmann-Kollmann M
Mycoses; 1997 Nov; 40(7-8):243-7. PubMed ID: 9476505
[TBL] [Abstract][Full Text] [Related]
12. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.
Seebacher C; Nietsch KH; Ulbricht HM
Cutis; 2001 Aug; 68(2 Suppl):17-22. PubMed ID: 11665724
[TBL] [Abstract][Full Text] [Related]
14. A clinical and laboratory study of ciclopirox olamine (8% Batrafen) in the treatment of onychomycosis.
Yu B; Zhou G; Wang B; Ben Y; Yan H; Shao Y; Wang B
Chin Med Sci J; 1991 Sep; 6(3):166-8. PubMed ID: 1838936
[TBL] [Abstract][Full Text] [Related]
15. Development of ciclopirox nail lacquer with enhanced permeation and retention.
Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
Gupta AK
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
[TBL] [Abstract][Full Text] [Related]
17. [Therapy with ciclopirox lacquer of onychomycoses caused by molds].
Ulbricht H; Wörz K
Mycoses; 1994; 37 Suppl 1():97-100. PubMed ID: 7854374
[TBL] [Abstract][Full Text] [Related]
18. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.
Brenner MA; Harkless LB; Mendicino RW; Page JC
J Am Podiatr Med Assoc; 2007; 97(3):195-202. PubMed ID: 17507527
[TBL] [Abstract][Full Text] [Related]
19. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers.
Hafeez F; Hui X; Selner M; Rosenthal B; Maibach H
Drug Dev Ind Pharm; 2014 Jun; 40(6):838-44. PubMed ID: 23600655
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial.
Zalacain-Vicuña AJ; Nieto C; Picas J; Martínez H; Bermejo R; Corrales A; Campos FF; Igea SA; Otero-Espinar FJ; Briones VG
Mycoses; 2023 Jul; 66(7):566-575. PubMed ID: 36336989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]